U.S. Distributes 150,985 mAbs Including Bebtelovimab

The U.S.  HHS Office of the Assistant Secretary for Preparedness and Response confirmed on February 14, 2022; it would distribute 150,985 anti-SARS-CoV-2 monoclonal antibody (mAbs) treatments to states, territories, and agencies this week.

The State/Territory/ Federal Entity mAbs distribution list is posted on this HHS webpage.

Since Sept. 24, 2021, the U.S. government has distributed about 3.45 million mAbs.

There are now three U.S. FDA Authorized mAbs available for use in the U.S.

The new allocation includes 48,745 mAbs doses of the recently Authorized Bebtelovimab, produced by Eli Lilly and Co.

As of Feb. 10, 2022, the U.S. NIH's OpenData Portal identified which mAbs are effective against SARS-CoV-2 coronavirus variants, including Omicron and the BA.2 subvariant.

And a JAMA Network Research Letter published on Feb. 4, 2022, confirmed specific mAbs are highly effective in treating mild to moderate COVID-19 among nonhospitalized patients.

These mAbs treatments block the SARS-CoV-2 virus from entering cells in the human body.

Additional mAbs breaking news is published at PrecisionVaccinations/antibodies.